Business UpdateApr 26, 2026, 05:20 AM
AGMB Reports €62.5M Loss in 2025; Needs Funding; Cash to H1 2029
AI Summary
Agomab Therapeutics NV, a clinical-stage biopharmaceutical company, reported a total comprehensive loss of €62.5 million for the year ended December 31, 2025, following a €46.4 million loss in 2024. The company's cash, cash equivalents, and cash investments stood at €116.5 million as of December 31, 2025, expected to fund operations into the first half of 2029. Agomab anticipates significant future losses and will require additional funding to advance its product candidates, including ontunisertib, AGMB-447, and AGMB-101, through lengthy and uncertain clinical development. The company also highlighted past material weaknesses in internal control over financial reporting.
Key Highlights
- Total comprehensive loss of €62.5 million for the year ended December 31, 2025.
- Total comprehensive loss of €46.4 million for the year ended December 31, 2024.
- Cash, cash equivalents, and investments were €116.5 million as of December 31, 2025.
- Existing capital expected to fund operations into the first half of 2029.
- Company is clinical-stage, expects significant future losses, and needs additional funding.
- Advancing ontunisertib, AGMB-447, and Phase 1-ready AGMB-101 product candidates.
- Identified past material weaknesses in internal control over financial reporting.